IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could protect kidneys in autoimmune diseases
Disease control Recruiting nowThis study tests a drug called atacicept in 200 adults and teens with autoimmune kidney diseases like IgAN and FSGS. The goal is to see if it safely reduces protein in the urine and helps preserve kidney function. Participants must already be on standard treatments and weigh at l…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for kidney disease: drug trial targets protein leak to save kidney function
Disease control Recruiting nowThis phase 3 study tests whether ravulizumab can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a disease that can lead to kidney failure. About 510 participants will receive either the drug or a placebo. The goal is to see if the drug sl…
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug ADX-038 aims to control rare kidney diseases
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have a…
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, which is a sign of kidney damage. Participants receive the drug through an IV and are monitored for sa…
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC